# Eisai Innovation

Eisai Innovation is a Corporate Venture Capital based in Cambridge, United States.

## Overview

- **Organization type:** Corporate Venture Capital
- **Headquarters:** Cambridge, United States
- **Region:** North America
- **Address:** Cambridge, MA, United States
- **Founded:** 2019
- **Assets under management:** Undisclosed
- **Website:** www.eisaiinnovation.com
- **LinkedIn:** https://www.linkedin.com/company/eisai-innovation-inc

## Regulatory record

- **Reports private funds:** No

## About

Eisai Innovation Inc. is a strategic investment organization aspiring to identify synergies between the scientific community and the Eisai network of companies. Its goals include strategic investment to create synergy with Eisai’s business, acquiring innovative assets and businesses, and establishing full-scale global Corporate Venture Investment capability. It targets Neurology & Oncology and their digital solutions and Diagnostics, with investments of about $5 M USD and roughly 10 years for exit.

## Sectors

- Digital Health
- Biotechnology
- Neurology
- Oncology
- Diagnostics

## Offices

- San Francisco, CA, United States

## People

- Yoshiharu Mizui — President
- Kou Qin — Managing Director of Investment
- Paul Wu — Investment Principal

## Questions

### Who runs investment decisions at Eisai Innovation?

Yoshiharu Mizui, the President who founded the unit in 2019, leads the investment team. He is supported by Managing Director Kou Qin in Cambridge and Investment Principal Paul Wu in San Francisco. The website lists these three as the investment leadership, and all have deep scientific backgrounds — Mizui and Qin hold PhDs — rather than purely financial profiles.

### Is Eisai Innovation a traditional venture capital fund or a corporate venture arm?

It is a wholly owned corporate venture capital arm of Eisai Co., Ltd. The unit invests the parent company's balance sheet directly, not capital from external limited partners. Its stated purpose is to add cutting-edge technologies, drug modalities, and digital healthcare solutions into the Eisai network.

### Which therapeutic areas and sectors does Eisai Innovation target?

Neurology and oncology are the two core disease-area mandates, mirroring the parent company's commercial strengths. The firm also invests in digital health solutions, diagnostics, and novel drug modalities that can complement those therapeutic focuses.

### Does Eisai Innovation invest only in the United States?

No. Its website lists a global remit that spans the United States, Europe, Japan, China, and emerging markets including Africa. The investment team currently operates from offices in Cambridge, Massachusetts and San Francisco, California.

### How is Eisai Innovation related to the broader Eisai corporate structure?

Eisai Innovation is a subsidiary investment entity formed by Eisai Co., Ltd., the publicly listed Japanese pharmaceutical company with roughly 10,000 employees worldwide. The parent company maintains regional operating units including Eisai Inc. in the United States and Eisai Europe Ltd., and the innovation arm is designed to feed acquired assets into that global commercial infrastructure.

### Does the firm accept unsolicited pitches from academic founders?

Yes. Its website explicitly invites contact from external parties and instructs them to specify whether the outreach concerns collaborations, investments, or general information. This open-door posture aligns with its stated goal of supporting academic-established startups.

## Related profiles

- [Eir Ventures](https://altss.com/profile/eir-ventures)
- [Eisvogel Group](https://altss.com/profile/eisvogel-group)

---

Last updated: 2026-08-11T15:06:35.052Z

Canonical page: https://altss.com/profile/eisai-innovation

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology